Current Status of Drug-Eluting Stents and Drug-Eluting Balloons for the Superficial Femoral Artery.
Current Status of Drug-Eluting Stents and Drug-Eluting Balloons for the Superficial Femoral Artery.
复制标题
股浅动脉药物洗脱支架和药物洗脱球囊的现状。
DOI：
10.1007/s40137-013-0018-x
复制
发表时间：
2013
影响因子：
0.6
通讯作者：
Owens,ChristopherD
中科院分区：
文献类型：
--
作者：
Walker,JoyP;Owens,ChristopherD
症状性动脉粥样硬化性股浅动脉疾病的血管内治疗具有挑战性，需要考虑独特的解剖学、血流动力学和生物力学因素。为了使创新的局部给药技术具有成本效益和临床意义，它们必须在更复杂的病变中提供相当于或上级目前批准的器械的通畅率。已经发表或最近提出了几项概念验证试验，还有更多的试验正在进行中，表明这些混合器械在减少再狭窄方面的生物学有效性。局部给药技术已经在一些国家的各种临床环境中商业化推广。然而，尽管这些技术在改善下肢介入治疗后的结局方面提供了希望，但谨慎和安全性至关重要。仍需长期随访（3-5年）的高效能、多中心、设计良好的随机对照试验来准确评估安全性和有效性。
The endovascular management of symptomatic atherosclerotic superficial femoral artery disease is challenging and requires consideration of unique anatomic, hemodynamic, and biomechanical factors. For innovative local drug delivery technologies to have a cost-effective and clinically meaningful benefit, they must provide patency rates in more complex lesions equivalent or superior to those currently approved devices are able to provide. Several proof-of-concept trials have either been published or been recently presented and many more are in the pipeline suggesting biologic effectiveness of these hybrid devices in reducing restenosis. Local drug delivery technology has already been commercially introduced in some countries for a variety of clinical settings. However, although these technologies offer promise in improving outcomes following lower extremity intervention, caution and safety are paramount. Adequately powered, multicenter, well-designed, randomized controlled trials with long-term follow-up (3–5 years) are still needed to accurately assess safety and efficacy.